Erlocip Erlotinib Tablets

Erlocip Erlotinib Tablets Specification

Dosage Form
Tablet

Salt Composition
Erlotinib Hydrochloride

Indication
Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

Enzyme Types
Tyrosine Kinase Inhibitor

Feature
Targeted cancer therapy; precise EGFR inhibition

Ingredients
Erlotinib Hydrochloride and excipients

Application
Oral administration for cancer treatment

Physical Color/Texture
White to off-white tablets

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits EGFR Tyrosine Kinase

Storage Instructions
Store below 30C, protect from moisture

Shelf Life
24 months

Patient Group
Adults

Registration Status
Approved by regulatory authorities

Route of Administration
Oral

Contraindications
Hypersensitivity to Erlotinib

Therapeutic Class
Antineoplastic

Standard Packaging
Blister strips in carton

Available Strengths
100 mg, 150 mg

Prescription Status
Prescription only

Pack Size
30 tablets per box

Usage Instructions
As directed by oncologist or physician

About Erlocip Erlotinib Tablets

Erlocip otherwise called Erlotinib is a doctor prescribed medication utilized as a part of the treatment of non-little cell lung disease and pancreatic malignancy. It interferes with the protein epidermal development factor, keeping it from enacting catalysts which is required in certain growth cells to develop and duplicate.

Manufacturer : Cipla Ltd.

Additional Information :

Dosage Available: 100mg and 150mg
Storage : Store in a cool dry place
Dose : ERLOCIP Tablets treatment must be administered by a doctor experienced in the utilization of hostile to growth treatments.

Prescribed Dose : NSCLC

EGFR transformation testing must be performed before start of ERLOCIP Tablets treatment in chemo-guileless patients with cutting edge or metastatic NSCLC.

The suggested day by day measurement of ERLOCIP Tablets for NSCLC is 150 mg gone up against an unfilled stomach no less than 1 hour prior or 2 hours after the ingestion of nourishment. Treatment should proceed until malady movement or inadmissible danger happens. There is no confirmation that treatment past movement is advantageous.

Prescribed Dose : Pancreatic Cancer

The prescribed every day measurement of ERLOCIP Tablets for pancreatic growth is 100 mg gone up against a vacant stomach no less than 1 hour prior or 2 hours after the ingestion of sustenance, in mix with gemcitabine. Treatment should proceed until infection movement or unsuitable lethality happens.
In patients who don't create rash inside the initial 4- two months of treatment, facilitate treatment with ERLOCIP Tablets ought to be re-surveyed.
At the point when dosage change is essential, the measurement ought to be lessened in ventures of 50 mg. Corresponding utilization of CYP3A4 substrates and modulators may require dosage modification.

Indications :

Most regular reactions are Nausea, Vomiting, Fatigue, Breathing trouble, Abdominal agony, Edema, Weight misfortune, Loss of craving, Anemia, Infection, Bone torment, Constipation, Diarrhea, Fever, Stomatitis (Inflammation of the mouth), Rash.

PACK SIZE : Pack of 30 tablets

Precise EGFR Inhibition for Cancer Treatment

Erlocip Erlotinib Tablets deliver targeted therapy by selectively inhibiting the EGFR tyrosine kinase enzyme, a critical factor in certain cancer growth pathways. This precision in treatment contributes to improved outcomes for eligible adults with non-small cell lung cancer or pancreatic cancer, making Erlocip an effective option under professional supervision.

Convenient Oral Administration and Secure Packaging

Designed for oral use, Erlocip tablets are easy to administer, improving patient compliance. The tablets are packaged in blister strips within a carton, ensuring stability and hygiene during storage and distribution. This helps maintain the products efficacy over its 24-month shelf life when stored below 30C and protected from moisture.

FAQs of Erlocip Erlotinib Tablets:

Q: How should Erlocip Erlotinib Tablets be taken for cancer treatment?

A: Erlocip Erlotinib Tablets are intended for oral administration as directed by your oncologist or physician. The exact dose and treatment schedule depend on your diagnosis and medical condition.

Q: What types of cancer is Erlocip indicated for?

A: Erlocip is primarily indicated for adults diagnosed with non-small cell lung cancer (NSCLC) and pancreatic cancer. Your healthcare provider will determine whether this therapy is suitable for your case.

Q: When is it necessary to use Erlocip Erlotinib Tablets?

A: Erlocip is used when a physician has prescribed it for eligible adult patients with NSCLC or pancreatic cancer, based on specific clinical requirements and disease progression.

Q: Where can Erlocip Erlotinib Tablets be obtained?

A: Erlocip is available through approved dealers, distributors, exporters, suppliers, traders, and wholesalers in India, but it is only dispensed with a valid prescription from a licensed medical professional.

Q: What processes does Erlocip target within the body?

A: Erlocip acts as an EGFR tyrosine kinase inhibitor, blocking the enzymatic activity responsible for cancer cell growth and survival in certain cancers, leading to targeted therapeutic benefits.

Q: What are the benefits of using Erlocip for cancer therapy?

A: Erlocip offers precise inhibition of EGFR, which helps slow down or halt cancer progression in many cases. When used properly under medical guidance, this targeted approach may improve clinical outcomes and quality of life.

Q: What precautions should patients take regarding the storage and usage of Erlocip?

A: Patients should store Erlocip tablets below 30C and protect them from moisture to maintain efficacy. The tablets must not be used by individuals with hypersensitivity to Erlotinib, and should always be taken according to the physicians instructions.

Get Latest Price